Hyman Stadlen, MD
Internal Medicine · Peekskill, NYNPI 1700924503
Payments from drug & device makers
Across 215 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$672
- Lundbeck LLC$360
- Bayer$264
- Johnson & Johnson$264
- Pfizer$201
- plus $856 from 17 others
What the payments were for
- Food & beverage$5,291100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 101 | $2,681 |
| Novo Nordisk | 37 | $672 |
| Lundbeck LLC | 16 | $360 |
| Bayer | 10 | $264 |
| Johnson & Johnson | 12 | $264 |
| Pfizer | 9 | $201 |
| Otsuka America Pharmaceutical, Inc. | 3 | $166 |
| Lilly USA, LLC | 6 | $152 |
| Mylan Specialty L.p. | 1 | $125 |
| Exact Sciences | 3 | $80 |
| Avanir Pharmaceuticals, Inc. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $44 |
| Amneal Pharmaceuticals LLC | 2 | $43 |
| CMP Pharma, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,298 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 152 | $74,558 |
| XareltoRivaroxaban | 128 | $55,489 |
| FarxigaDapagliflozin Propanediol | 44 | $29,421 |
| JardianceEmpagliflozin | 45 | $21,545 |
| Glatiramer Acetate | 12 | $18,796 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $15,618 |
| JanuviaSitagliptin Phosphate | 32 | $13,815 |
| RetacritEpoetin Alfa-Epbx | 44 | $13,508 |
| MounjaroTirzepatide | 12 | $12,533 |
| SantylCollagenase Clostridium Hist. | 15 | $10,916 |
| Atorvastatin Calcium | 624 | $10,322 |
| EntrestoSacubitril/Valsartan | 25 | $9,821 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $8,470 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 65 | $7,581 |
| Aripiprazole | 21 | $6,978 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Retacrit | $201 | $88,066196 claims |
| Johnson & JohnsonXarelto | $264 | $55,489128 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $17 | $30,01662 claims |
| AstraZenecaFarxiga | $2,681 | $29,42144 claims |
| Lilly USA, LLCMounjaro | $152 | $12,53312 claims |
| NovartisEntresto | $18 | $9,82125 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $5,63025 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $43 | $3,444232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Peekskill
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.